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Editorial on the Research Topic
Bacterial Mechanisms of Antibiotic Resistance: A Structural Perspective
Antibiotic-resistant bacteria are responsible for millions of hard-to-treat infections annually. Since
antibiotic “miracle drugs” were first introduced into clinical use, resistance has closely followed;
more recently, this problem has been greatly exacerbated by their extensive use in medicine
and agriculture, combined with the remarkable ability of bacterial populations to rapidly evolve
and exchange genetic material. The rise of multidrug resistance (MDR), coupled with declining
availability of newly approved or in-development treatments, threatens to fundamentally alter our
ability to treat infections. Whether the most pessimistic predictions of a future “post-antibiotic
era” become reality over the coming decades will depend on actions taken in the present. This
Research Topic collects together articles that highlight the recent contributions of structural
biology and related approaches to our understanding of antibiotic resistance and adaptions used
by bacteria against drugs that target key cellular structures, complexes or pathways, as well as drug
development efforts to counter these resistance mechanisms. New insights from such approaches
are likely to be critical in future efforts to develop strategies to overcome existing resistance
mechanisms and to identify targets for novel antibiotic development.
EFFLUX PUMPS AND TRANSPORTERS
The tripartite assemblies built around the Resistance-Nodulation-Division (RND) family of
proton-powered secondary transporters play a prominent MDR role in Gram-negative bacteria.
While RND assemblies have been a focus of a recent dedicated Frontiers Research Topic (Vargiu
et al., 2016), their structural biology is one of themost rapidly advancing directions within theMDR
field and two important experimental studies are reported within this collection.
First, Zwama et al. use X-ray crystallography to dissect the role of the so-called hoisting loop,
located at the border of transmembrane helix 8 and the PC2 subdomain, in the prototypical
RND family member AcrB. This study demonstrates how the random coil-to-α-helix transition
of this loop leads to opening and closing of the drug-channel entrance. Crucially, this work
elucidates one of the last remaining problematic areas regarding the functional RND-pump
cycle, namely the energy transduction and conformational coupling between remote regions of
the RND-transporters.
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Another persistent question within the RND field is the
structural basis for the apparent broad-substrate specificity
provided by these pumps. Ramaswamy et al. address this using
molecular dynamics simulations of the centrally important
RND-transporters MexB and MexY from Pseudomonas
aeruginosa. This study characterizes the potential binding
pockets of these transporters and their substrates which,
by innovative use of electrostatic complementarity analysis,
allows the authors to reveal key differences between these
transporters. Importantly, this first comparative study of
the major P. aeruginosa transporters suggests that the deep
binding pocket of the tight conformer plays a central role in
substrate selectivity.
While the role of RND transporters in eﬄux and tripartite
assemblies has been extensively studied, until recently, much
less was known about the structural organization of the ABC-
transporter family members participating in tripartite assemblies.
A wide-ranging review by Greene et al. synthesizes the recent
advances in structure and function of the MacB-family of ABC-
transporters, which form unique tripartite assemblies with a role
in macrolide eﬄux and protein export. The authors provide a
tantalizing novel model of functional mechanotransmission and
discuss the links to homologous tripartite systems from other
pathogenic bacteria, which similarly export protein-like signaling
molecules, virulence factors, and siderophores.
Genetic regulation of eﬄux pumps is a key mechanism
of resistance, with their associated transcriptional regulators
emerging as promising therapeutic targets, and yet, this remains
one of least well-understood areas in MDR. Bridging this gap,
Issa et al., provide a comprehensive review of the recent progress
in the structural biology of regulator families in P. aeruginosa,
including the one-component system regulators of the TetR,
LysR, MarR, AraC families, and two-component systems (TCS)
families of regulators. In a related work, Milton et al., combine
molecular modeling with biochemical and cellular studies to
propose a potential mechanism of interaction between TCS
response regulators and 2-aminoimidazole compounds which
can inhibit bacterial biofilm formation, disperse preformed
biofilms, and re-sensitize MDR bacteria to antibiotics. This study
focuses on two important pathogens, Acinetobacter baumannii
and Francisella tularensis, and provides promising new insights
into this potential new therapeutic avenue.
CELL WALL ALTERATIONS
The complex role played by the bacterial cell-envelope structure,
and particularly the lipid A (endotoxin) component of
lipopolysaccharide (LPS) outer membrane layer, in modulating
the bacterial susceptibility to host antimicrobials such as cationic
antimicrobial peptides, is subject to an in-depth review by
Kahler et al.. The role of LPS in bacterial pathogenesis and
immunological evasion has recently been the focus of increased
attention and this work provides a timely summary of the
knowledge of the effects of phosphoethanolamine decoration
of lipid A in pathogenic Neisseria strains and the potential of
targeting the EptA-enzyme responsible for therapeutic purposes.
Another way bacteria protect themselves against external
agents is by altering the peptidoglycan (PG) cell wall and a
well-known example is replacing the D-Ala moiety of PG to
D-lactate to confer vancomycin resistance in enterococci. In
their review article, Yadav et al. explain how various chemical
modifications to PG help defend bacteria against host-generated
antimicrobials, such as lysozyme and other hydrolytic enzymes,
as well as antibiotics. Such knowledge can help guide new
therapeutic approaches that weaken the bacterial cell wall and
increase susceptibility to existing antibiotics.
RIBOSOME-TARGETING ANTIBIOTICS
AND RESISTANCE MECHANISMS
Ribosomes are the essential RNA-protein complexes responsible
for protein synthesis in all cells. However, unique aspects of the
bacterial ribosome allow for specific antibiotics that interfere
with every aspect of ribosome function. These chemically diverse
drugs have been a major component of our clinical arsenal for
many decades and three articles here focus on their action and
associated resistance mechanisms.
Polikanov et al. provide a detailed review of ribosome-
targeting peptide antibiotics, with specific emphasis on each
drug’s interaction with either the small (30S) or large (50S)
ribosome subunit and mechanism of action. Accumulating
information on these antibiotics, including high-resolution
ribosome-drug structures, offers opportunities to develop
improved, next generation antibiotics with enhanced activity
and, through modification of regions dispensable for ribosome
inactivation, improvements in other properties such as
uptake/retention or reduced toxicity.
Markley and Wencewicz describe the known mechanisms of
resistance to tetracyclines, drugs that have been in clinical use for
over 60 years. Resistance via eﬄux, ribosome modification, and
the action of ribosome protection proteins are well-established,
but their effects have been successfully countered through the
design of more recent generations of tetracyclines such as
tigecycline. However, these drugs are also now threatened by the
emergence of the tetracycline-inactivating enzymes, which are
the main focus of this review. Similarly, Golkar et al. describe
the chemical structures, mechanisms of action, and resistance
for a second major class of drugs, the macrolides, which
bind in the peptide exit tunnel. Like tetracyclines, macrolides
are subject to resistance via eﬄux, ribosome modification or
mutation, and protection proteins. Additionally, their efficacy is
also threatened by macrolide modifying phosphotransferase and
esterase enzymes, the structures, and activities of which are the
major focus of this comprehensive review.
SULFONAMIDES AND β-LACTAMASES:
RESISTANCE AND FRONTIERS IN DRUG
DEVELOPMENT
Sulfa drugs (sulfonamides) were first introduced in the 1930s
and have a long history of efficacy against bacterial disease.
These drugs inhibit bacterial dihydropteroate synthase (DHPS)
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by mimicking one of its substrates, para-aminobenzoic acid
(PABA). Mutations in DHPS cause resistance to sulfonamides
but their mechanism is often unknown. Griffith et al. identify
five mutations of DHPS associated with sulfonamide resistance
in Staphylococcus aureus and investigate their impacts on strain
susceptibility and fitness, and enzyme kinetics. Three of the
mutations contribute to resistance by sterically blocking the outer
ring moiety of sulfonamides, whereas the other two increase
fitness of the strain. The work reveals a critical weakness
of sulfonamides with implications for drug design: resistance
mutations target the part of the antimicrobial that is most
important for its efficacy.
Discussion of antimicrobial resistance would not be complete
without mention of β-lactamases, a common mechanism of
resistance in bacteria, including the ESKAPE pathogens. These
enzymes hydrolyze β-lactam antibiotics before they reach their
molecular targets, the so-called penicillin-binding proteins.
In his review, Palzkill explains the molecular basis for the
differing specificities of three important groups of Class A β-
lactamases (the TEM, CTX-M, and KPC enzymes) for oxyamino-
cephalosporins. He highlights mutations that increase the
conformational heterogeneity within the active sites of these
enzymes to accommodate cephalosporins and the existence
of global suppressor mutations elsewhere in the protein to
compensate for loss of stability. Finally, in their review, van den
Akker and Bonomo describe extensive efforts by a number of
groups to develop β-lactamase inhibitors, including five approved
for clinical use. They emphasize the success of strategies that
exploit specific aspects of enzyme mechanism in the design of
these critical antimicrobial agents.
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